| human | Q5 |
| P6178 | Dimensions author ID | 01200667473.07 |
| P2798 | Loop ID | 396513 |
| P856 | official website | https://researchnow.flinders.edu.au/en/persons/338e2d7b-f920-4ec7-a74f-7e86a9841be3 |
| P496 | ORCID iD | 0000-0001-6668-9638 |
| P1153 | Scopus author ID | 55873211800 |
| P10861 | Springer Nature person ID | 01200667473.07 |
| P69 | educated at | Flinders University | Q15575 |
| Royal Australasian College of Physicians | Q7373726 | ||
| P108 | employer | Flinders University | Q15575 |
| Flinders Medical Centre | Q5459413 | ||
| Flinders University School of Medicine | Q99298592 | ||
| P106 | occupation | researcher | Q1650915 |
| Q38918161 | A Treat-to-Target Strategy Preserves Work Capacity in a Rheumatoid Arthritis Inception Cohort Treated With Combination Conventional DMARD Therapy. |
| Q50159928 | A multi centre retrospective analysis evaluating performance of synovial biopsy techniques: arthroscopic vs. ultrasound guided vs. blind needle biopsy |
| Q81954328 | Achalasia cardia presenting as stridor |
| Q39908952 | Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission |
| Q82773510 | Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement |
| Q53122503 | Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. |
| Q79468359 | An extension of pancreatic pseudocysts in the neck |
| Q39042968 | Arthroscopic guided synovial biopsy in rheumatology: current perspectives |
| Q38813486 | CD40L-Dependent Pathway Is Active at Various Stages of Rheumatoid Arthritis Disease Progression. |
| Q35224179 | Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years |
| Q24194373 | Colchicine for acute gout |
| Q40182957 | Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis |
| Q48282881 | Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. |
| Q40847456 | Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term? |
| Q39596343 | Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort |
| Q84833925 | Esophageal adenocarcinoma and hypertrophic osteoarthropathy with improvement following resection of esophageal cancer |
| Q92236377 | Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients |
| Q41924055 | Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. |
| Q53081333 | Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. |
| Q55027964 | Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. |
| Q24193902 | Interleukin-1 inhibitors for acute gout |
| Q24197569 | Intra-articular glucocorticoids for acute gout |
| Q24197587 | Intra-articular glucocorticoids for acute gout |
| Q95844002 | Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis |
| Q41948603 | Multicentric myofibroblastic sarcoma |
| Q37553140 | Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative |
| Q96640234 | Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy |
| Q24193584 | Non-steroidal anti-inflammatory drugs for acute gout |
| Q34479870 | Nonsteroidal anti-inflammatory drugs for treatment of acute gout. |
| Q53109365 | Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro. |
| Q49618356 | PD‑1+ T cells contribute differently to the pathogenesis of rheumatoid arthritis and psoriatic arthritis. |
| Q59794790 | Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups |
| Q92181459 | Synovial biopsies in inflammatory arthritis: precision medicine in rheumatoid arthritis |
| Q37689670 | Th17 and Th22 cells in psoriatic arthritis and psoriasis |
| Q91062214 | The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis |
| Q38245441 | The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors |
| Q93013398 | The novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblasts |
| Q35236591 | Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review |
| Q38597826 | Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways. |
| Q34047769 | Utility of arthroscopic guided synovial biopsy in understanding synovial tissue pathology in health and disease states |
Search more.